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The p38 mitogen-activated protein (MAP) kinase signal transduction pathway is activated by proinflam-
matory cytokines and environmental stress. The detection of p38 MAP kinase in the nucleus of activated cells
suggests that p38 MAP kinase can mediate signaling to the nucleus. To test this hypothesis, we constructed
expression vectors for activated MKK3 and MKK6, two MAP kinase kinases that phosphorylate and activate
p38 MAP kinase. Expression of activated MKK3 and MKK6 in cultured cells caused a selective increase in p38
MAP kinase activity. Cotransfection experiments demonstrated that p38 MAP kinase activation causes in-
creased reporter gene expression mediated by the transcription factors ATF2 and Elk-1. These data demon-
strate that the nucleus is one target of the p38 MAP kinase signal transduction pathway.
Several mitogen-activated protein (MAP) kinase signal
transduction pathways have been detected in mammalian cells
(15). Three groups of MAP kinases have been molecularly
cloned: ERK (7, 8), JNK (16, 22, 31, 34, 55), and p38 (27, 35,
47). These MAP kinases are activated by dual phosphorylation
on Thr and Tyr within the motif Thr-Xaa-Tyr in subdomain
VIII (15). The sequence of this dual phosphorylation motif
differs for each MAP kinase group as follows: p38, Thr-Gly-
Tyr; JNK, Thr-Pro-Tyr; and ERK, Thr-Glu-Tyr. Each MAP
kinase group has a distinct substrate specificity and is regulated
by a separate signal transduction pathway (15). Mammalian
cells therefore contain multiple MAP kinase signal transduc-
tion pathways that mediate the effects of extracellular stimuli
on a wide array of biological processes.
Detailed studies of the JNK and ERK groups of MAP kinase
have led to significant insight into the physiological function of
these signaling pathways (6, 13–15, 40, 45). In contrast, the role
of the p38 MAP kinase signal transduction pathway is poorly
understood (20, 27, 35, 44, 47). p38 MAP kinase is weakly
activated by protein kinase C and receptor tyrosine kinases but
is strongly activated by the treatment of cells with inflamma-
tory cytokines (e.g., tumor necrosis factor and interleukin-1)
and environmental stress (e.g., osmotic shock and UV radia-
tion) (20, 27, 35, 44, 47). The contribution of the p38 MAP
kinase pathway to the cellular response to these stimuli has not
been established. However, recent studies have implicated p38
MAP kinase in the phosphorylation of the small heat shock
protein Hsp27 (20, 47), in increased cytokine expression (35),
and in programmed cell death (61). Furthermore, in vitro
protein kinase assays demonstrate that p38 MAP kinase phos-
phorylates MAPKAP kinase-2 (20, 47) and the transcription
factor ATF2 (17, 44).
The mechanism of p38 MAP kinase activation is mediated
by dual phosphorylation on Thr and Tyr within the motif Thr-
Gly-Tyr located in subdomain VIII (44). The p38 MAP kinase
activator MKK3 has been molecularly cloned (17). MKK3 is a
protein kinase that phosphorylates and activates p38 MAP
kinase but does not phosphorylate the related JNK or ERK
MAP kinases (17). MKK3 is therefore a specific activator of
p38 MAP kinase that is independent of the JNK and ERK
signaling pathways. A second MAP kinase kinase, MKK4,
phosphorylates and activates both p38 MAP kinase and JNK in
vitro (17, 36). Additional components of the p38 MAP kinase
pathway have not been identified. However, the Rho family
GTPases Rac1 and Cdc42 (5, 11, 41, 42, 62) and the STE20-
related protein kinases PAK-1 (62), PAK-3 (5), and GC kinase
(43) have been implicated in the p38 MAP kinase and JNK
signaling pathways.
The purpose of this study was to examine the functional
consequence of p38 MAP kinase activation in vivo. Cytokines
and environmental stress activate several signal transduction
pathways, including p38 MAP kinase. Identification of re-
sponses that are causally related to p38 MAP kinase activation
is therefore difficult. Here we describe the molecular cloning of
a novel activator of p38 MAP kinase (MKK6) that is related to
MKK3. Dominant-active mutant forms of MKK3 and MKK6
were employed to selectively activate the p38 MAP kinase
signal transduction pathway in cultured cells. This experimen-
tal approach allows the functional dissection of the p38 MAP
kinase signal transduction pathway in vivo. We report that p38
MAP kinase can mediate signaling to the nucleus.
MATERIALS AND METHODS
Materials. Flag-MKK3 (17) was subcloned into pRc/RSV (Invitrogen, Inc.) at
the HindIII and SpeI restriction sites to create the expression vector pRSV-Flag-
MKK3. Dominant-active MKK3 [MKK3(Glu)] and dominant-negative MKK3
[MKK3(Ala)] were constructed by replacing Ser-189 and Thr-193 with Glu and
Ala residues, respectively. The mutations were made by overlapping PCR (28),
and the sequence was confirmed with a model 373A DNA sequencer (Applied
Biosystems, Inc.). The expression vectors for epitope-tagged p38 (17, 44),
epitope-tagged JNK1 (16), MEK1 with mutations of S-218 to E and S-222 to D
(S218E/S222D MEK1) (38), and DN3/S218E/S222D MEK1 (where residues 32
to 51 deleted) (38) have been described previously. The expression vector for
hemagglutinin (HA)-tagged ERK2 was provided by M. Weber. Bacterial expres-
sion of glutathione S-transferase (GST)-ATF2, GST-ERK2, GST–Elk-1, GST-
Jun, GST-p38, and GST-JNK1 has been described previously (4, 16, 23, 60). The
Flag peptide Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys was obtained from Chiron
Corp.
Molecular cloning of MKK6. Human MKK6 cDNA clones were isolated from
a skeletal muscle library (Stratagene, Inc.) by screening with an MKK3 probe at* Corresponding author.
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low stringency. Both of the largest clones obtained (1,699 and 2,942 bp) included
the entire coding region of MKK6. However, the sequences of these clones
differed in the 39 noncoding region. The Flag epitope (-Asp-Tyr-Lys-Asp-Asp-
Asp-Asp-Lys-; Immunex Corp.) was inserted between codons 1 and 2 of MKK6
by insertional overlapping PCR (28). A similar PCR procedure was used to
replace Lys-82 with Ala to create MKK6(K82A) and to replace Ser-207 and
Thr-211 with Glu to create MKK6(Glu). Mammalian MKK6 expression vectors
were constructed by subcloning the MKK6 cDNA in the HindIII and XbaI sites
of pCDNA3 (Invitrogen, Inc.). A bacterial MKK6 expression vector was con-
structed by subcloning the MKK6 cDNA in the EcoRI and XbaI sites of
pGEX-3X (Pharmacia LKB Biotechnology, Inc.).
The sequences of all plasmids were confirmed by automated sequencing with
an Applied Biosystems model 373A machine.
Tissue culture. Chinese hamster ovary cells were maintained in Ham’s F12
medium supplemented with 5% fetal bovine serum. COS-1 cells were maintained
in Dulbecco’s modified Eagle’s medium supplemented with 5% fetal bovine
serum (Gibco-BRL). Plasmid DNA (1 mg) was transfected by the Lipofectamine
method (Gibco-BRL), and the cells were harvested after 48 h of incubation.
Protein kinase isolation. The cells were exposed to 40 J of UV-C radiation per
m2 (60 min) and solubilized with buffer A (20 mM Tris [pH 7.5], 10% glycerol,
1% Triton X-100, 0.137 M NaCl, 25 mM b-glycerophosphate, 2 mM EDTA, 0.5
mM dithiothreitol, 1 mM orthovanadate, 2 mM PPi, 10 mg of leupeptin per ml,
1 mM phenylmethylsulfonyl fluoride). The extracts were centrifuged at 100,000
3 g for 15 min at 48C. Epitope-tagged protein kinases were immunoprecipitated
by incubation for 2 h at 48C with the M2 Flag monoclonal antibody (IBI-Kodak)
or HA monoclonal antibody (BAbCo) bound to protein G-Sepharose (Pharma-
cia LKB Biotechnology, Inc.). Endogenous p38 MAP kinase was immunopre-
cipitated with a rabbit polyclonal p38 antibody prebound to protein A-Sepharose
(44). The immunoprecipitates were washed twice with buffer A and twice with
kinase buffer (25 mM HEPES [N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic
acid; pH 7.4], 25 mM b-glycerophosphate, 25 mMMgCl2, 0.5 mM dithiothreitol,
0.1 mM sodium orthovanadate). Elution of Flag-tagged protein kinases from M2
immunoprecipitates was performed by incubation for 2 h at 48C with 100 mg of
Flag peptide Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys per ml.
Protein kinase assays. Recombinant protein kinases (100 ng), soluble immu-
nopurified protein kinases, or protein kinase immunoprecipitates were employed
for kinase assays. The reactions were initiated by the addition of 1 mg of substrate
proteins (ATF2, Elk-1, c-Jun, ERK2, p38, or JNK1) and 50 mM [g-32P]ATP (10
Ci/mmol) in a final volume of 40 ml of kinase buffer. The reactions were termi-
nated after 30 min at 258C by addition of Laemmli sample buffer. The phos-
phorylation of the substrate proteins was examined after sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) by autoradiography.
Hybridization analysis.Northern (RNA) blot analysis was done with poly(A)1
mRNA (2 mg) isolated from different human tissues (Clontech, Inc.). The
mRNA was fractionated by denaturing agarose gel electrophoresis and trans-
ferred to a nylon membrane. The blot was probed with the MKK6 cDNA labeled
by random priming with [a-32P]dATP (Amersham International PLC).
Reporter gene expression. Cotransfection assays were performed with CHO
cells. The luciferase reporter plasmids were pSRE-Luc (60), 279/1170jun-Luc
(18), TNFa-Luc (provided by S. McKnight), CMV-Luc (53), SV40-Luc (53),
HIV LTR-Luc (provided by W. Greene), HTLV-1 LTR-Luc (provided by W.
Greene), and pRSV-Luc (53). The activities of the GAL4 DNA binding domain
(49), GAL4/ATF2 (23), GAL4/ElkC (39), GAL4/Jun (31), and GAL4/VP16 (48)
were measured in cotransfection assays with the reporter plasmid pG5E1bLuc
(53). This reporter plasmid contains five GAL4 sites cloned upstream of a
minimal promoter element and the firefly luciferase gene. Transfection efficiency
was monitored by using a control plasmid that expresses b-galactosidase
(pCH110; Pharmacia LKB Biotechnology, Inc.). The luciferase and b-galactosi-
dase activity detected in cell extracts was measured (23, 24).
RESULTS
MKK3 causes increased p38 MAP kinase activity. The
MKK3 protein kinase is activated by dual phosphorylation on
Ser-189 and Thr-193 (17). The mechanism of MKK3 activation
may be mediated by increased negative charge at the sites of
phosphorylation. We therefore examined the effect of intro-
ducing a constitutive negative charge by replacing Ser-189 and
Thr-193 with Glu. The wild-type and mutated MKK3 proteins
were isolated from cells exposed to 0 and 40 J of UV-C per m2.
MKK3 protein kinase activity was measured in an immune
complex assay using GST-p38 as a substrate (17). Figure 1A
shows that UV irradiation caused increased activity of wild-
type MKK3. In contrast, the MKK3(Glu) protein kinase was
not regulated by UV irradiation. The similar protein kinase
activities observed in assays of MKK3(Glu) and UV-stimu-
lated wild-type MKK3 indicate that MKK3(Glu) is constitu-
tively activated (Fig. 1A).
To test whether MKK3(Glu) causes constitutive p38 MAP
kinase activation in vivo, we performed cotransfection studies
using MKK3 and p38 MAP kinase. The p38 MAP kinase was
isolated by immunoprecipitation, and the protein kinase activ-
ity in the immune complex with the substrate ATF2 was mea-
sured (44). Figure 1B shows that MKK3(Glu) caused marked
activation of p38 MAP kinase. Control experiments demon-
strated that MKK3(Glu) activated wild-type p38 MAP kinase
(TGY) but not the phosphorylation-defective mutant (AGF)
lacking the sites of activating Thr and Tyr phosphorylation.
These data indicate that MKK3(Glu) causes increased p38
MAP kinase activity in vivo.
The constitutive activation of MKK3 caused by the replace-
ment of Ser-189 and Thr-193 with Glu suggests that the re-
placement of these residues with Ala [producing MKK3(Ala)]
would yield an inactive MKK3 protein kinase. Indeed, expres-
sion of MKK3(Ala) did not cause p38 MAP kinase activation
(Fig. 1B). To test whether the Ala substitution acts as a dom-
inant-interfering mutation, we investigated the effect of
MKK3(Ala) on p38 MAP kinase activity in cotransfection ex-
periments. Figure 1C shows that the expression of MKK3(Ala)
caused a marked reduction in UV-stimulated p38 MAP kinase
activity. Control experiments demonstrated that MKK3(Ala)
FIG. 1. Construction of a constitutively activated MKK3 protein kinase. The
MKK3 protein kinase is activated by phosphorylation on Ser-189 and Ser-193
(17). Mutated MKK3 protein kinases were created by replacement of both
phosphorylation sites with Glu or Ala. (A) Epitope-tagged wild-type MKK3 and
S189E/T193E MKK3 [MKK3(Glu)] were expressed in COS cells. The cells were
activated by exposure to 40 J of UV-C per m2 and incubated for 1 h. The MKK3
protein kinase activity was measured in an immune complex kinase assay using
GST-p38 MAP kinase as a substrate. (B) Constitutively activated MKK3(Glu)
was expressed in COS cells together with epitope-tagged wild-type p38 MAP
kinase (TGY) or mutated p38 MAP kinase (AGF). The mutated p38 MAP
kinase is not a substrate for MKK3, because it lacks the sites of activating
phosphorylation on Thr and Tyr (17). The p38 MAP kinase activity was mea-
sured in an immune complex kinase assay using GST-ATF2 as a substrate (17,
44). (C) Dominant-negative S189A/T193A MKK3 [MKK3(Ala)] was expressed
in COS cells together with epitope-tagged p38 MAP kinase. The cells were
exposed to 40 J of UV-C per m2 and incubated for 1 h. The p38 MAP kinase
activity was measured in an immune complex kinase assay using GST-ATF2 as a
substrate.
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also inhibited JNK activation, but it did not inhibit ERK acti-
vation (data not shown). The inhibition of both p38 and JNK
suggests that MKK3(Ala) may function by sequestering up-
stream MAP kinase kinase kinases that activate the JNK and
p38 MAP kinase signaling pathways.
Together, these data demonstrate that dominant-active and
dominant-negative MKK3 mutants are created by the replace-
ment of the sites of activating phosphorylation (Ser-189 and
Thr-193) with Glu and Ala, respectively.
MKK3 causes selective activation of p38 MAP kinase. The
MKK3 protein kinase phosphorylates and activates p38 MAP
kinase by dual phosphorylation on Thr and Tyr (17, 44). In
contrast, MKK3 does not phosphorylate JNK or ERK MAP
kinases (17). This analysis indicates that the expression of
constitutively activated MKK3 should cause selective activa-
tion of p38 MAP kinase in vivo. To test this hypothesis, we
examined the effect of MKK3(Glu) on p38, JNK, and ERK in
cotransfection assays. Figure 2A shows that MKK3(Glu)
caused activation of p38 MAP kinase but not JNK or ERK.
Control experiments demonstrated that activated MEK1
caused increased ERK activity but not increased p38 or JNK
activity (Fig. 2B). These data indicate that MKK3 causes se-
lective activation of the p38 MAP kinase signal transduction
pathway.
MKK3 causes increased reporter gene expression. We em-
ployed MKK3(Glu) to examine the functional consequence of
p38 MAP kinase activation in vivo. In initial experiments, we
examined the effect of activated MKK3 on the expression of a
luciferase reporter gene. Control experiments using activated
MEK1 to stimulate the ERK signal transduction pathway were
also performed. Figure 3 shows that the expression of activated
MEK1 increased luciferase expression in experiments using
reporter plasmids that contained viral, proto-oncogene, and
cytokine promoters. In contrast, MKK3(Glu) caused only a
small increase in reporter gene expression (data not shown).
This observation suggests that the ERK, but not the p38 MAP
kinase, signal transduction pathway regulates reporter gene
expression. However, control experiments demonstrated that
while activated MEK1 caused increased activity of both endo-
genous and cotransfected ERK, MKK3(Glu) caused a marked
increase in p38 MAP kinase activity only in cells that were
cotransfected with p38 MAP kinase (Fig. 2). MKK3(Glu)
caused only a small (twofold) increase in the activity of the
endogenous p38 MAP kinase (data not shown). The lack of a
marked effect of MKK3(Glu) on reporter gene expression may
therefore be caused by the failure of MKK3(Glu) to cause a
large increase in endogenous p38 MAP kinase activity. To test
this hypothesis, we examined the effect of coexpression of
MKK3(Glu) with p38 MAP kinase on reporter gene expres-
sion. We found that coexpression of MKK3(Glu) with p38
MAP kinase (Fig. 3), but not the expression of MKK3(Glu) or
p38 MAP kinase alone (data not shown), caused increased
reporter gene expression. This requirement for coexpression of
p38 MAP kinase with MKK3(Glu) indicates that the effects of
MKK3 on increased reporter gene expression are mediated by
FIG. 2. Constitutively activated MKK3 stimulates p38 MAP kinase but not
ERK or JNK. (A) COS cells were cotransfected with constitutively activated
MKK3(Glu) and an epitope-tagged MAP kinase (p38 MAP kinase, ERK2, or
JNK1). The cells were activated by exposure to 40 J of UV light per m2 (p38
MAP kinase and JNK1) or 100 nM phorbol myristate acetate (ERK2). MAP
kinase activity was measured in an immune complex kinase assay using ATF2 as
a substrate for p38 MAP kinase and JNK. ERK protein kinase activity was
measured by using the substrate GST-Myc. (B) Cells were cotransfected with
constitutively activated DN3/S218E/S222D MEK1 (38) and an epitope-tagged
MAP kinase (p38 MAP kinase, ERK2, or JNK1). The MAP kinase activity was
measured in an immune complex kinase assay using the substrate GST-Myc (for
ERK2) and GST-ATF2 (for p38 MAP kinase and JNK1).
FIG. 3. Selective activation of viral, proto-oncogene, and cytokine promoters
by the MKK3-p38 MAP kinase signal transduction pathway. CHO cells were
cotransfected with luciferase reporter plasmids and an empty expression vector
(Control) or expression vectors for MEK3(Glu) and p38 MAP kinase (p38) or
activated MEK1 (S218E/S222D) (ERK). A b-galactosidase expression vector
(pCH110) was employed to control for transfection efficiency. Cell extracts were
prepared at 48 h following transfection, and the activity of b-galactosidase and
luciferase was measured. The data are the means6 standard errors of the means
of the ratios of luciferase activity to b-galactosidase activity (n 5 3) and are
presented as the activity relative to that of control cells. (A) Reporter plasmids
with cytomegalovirus (CMV), Rous sarcoma virus (RSV), simian virus 40
(SV40), human immunodeficiency virus LTR (HIV), and HTLV-1 LTR (HTLV)
promoters; (B) reporter plasmids with the tumor necrosis factor alpha promoter
(TNF) or fragments of the c-jun (proximal AP-1 site) or c-fos (SRE) promoter.
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p38 MAP kinase. However, we are not able to exclude the
possibility that another (perhaps unidentified) MAP kinase
also contributes to the effects of MKK3(Glu).
The increased reporter gene expression caused by activated
MEK1 and MKK3 was observed in experiments using several
different reporter plasmids that contain viral, proto-oncogene,
and cytokine promoters (Fig. 3). However, small effects of
these activated MAP kinase kinases were observed in experi-
ments using reporter plasmids with Rous sarcoma virus and
simian virus 40 promoters. Larger increases in luciferase ex-
pression were found in experiments using reporter plasmids
with cytomegalovirus, human immunodeficiency virus long ter-
minal repeat (LTR), human T-cell leukemia virus type 1
(HTLV-1) LTR, and tumor necrosis factor alpha promoters or
fragments of the c-jun (proximal AP-1 site) and c-fos (SRE)
promoters. Together, these studies demonstrate that the p38
MAP kinase signal transduction pathway, like the ERK signal
transduction pathway, leads to increased gene expression.
The largest effects of MKK3(Glu) on reporter gene expres-
sion were observed in experiments using the HTLV-1 LTR
promoter, the c-fos SRE, and the c-jun proximal AP-1 site (Fig.
3). The mechanism that accounts for the increased gene ex-
pression is unclear. We therefore examined the effect of
MKK3(Glu) on reporter gene expression in a simpler experi-
mental model employing GAL4 fusion proteins. Cotransfec-
tion assays using a reporter plasmid with GAL4 DNA binding
sites cloned upstream of a luciferase gene were performed.
While the level of luciferase expression detected in experi-
ments using the GAL4 DNA binding domain was extremely
low, a high level of luciferase activity was found in cells trans-
fected with GAL4/VP16 (Fig. 4). Expression of MKK3(Glu)
caused a small increase in GAL4/VP16-dependent luciferase
expression (Fig. 4).
MKK3(Glu)-stimulated reporter gene expression was also
examined in experiments using the GAL4 DNA binding do-
main fused to the activation domains of the ATF2, c-Jun, and
Elk-1 transcription factors. MKK3(Glu) increased ATF2- and
Elk-1-dependent reporter gene expression but caused only a
small increase in Jun-dependent gene expression (Fig. 4). In
contrast, activated MEK1 increased Elk-1- and c-Jun-depen-
dent gene expression but not ATF2-dependent gene expres-
sion (Fig. 4). Control experiments demonstrated that the in-
creased gene expression was reduced by mutation of the
phosphorylation sites Thr-69 and Thr-71 (ATF2), Ser-63 and
Ser-73 (c-Jun), and Ser-383 (Elk-1) (Fig. 4). The activation of
ATF2 and Elk-1 by MKK3(Glu) suggests that these transcrip-
tion factors are targets of the p38 MAP kinase signal trans-
duction pathway. Indeed, p38 MAP kinase phosphorylates
ATF2 and Elk-1 but does not phosphorylate c-Jun (Fig. 4E).
These data demonstrate that the transcription factors ATF2
and Elk-1 can account, in part, for transcriptional regulation by
the MKK3-p38 MAP kinase signal transduction pathway.
However, an important caveat must be placed on this conclu-
sion because the activation of ATF2 and Elk-1 by MKK3(Glu)
requires the overexpression of p38 MAP kinase (Fig. 3). For
example, the overexpressed p38 MAP kinase may phosphory-
late proteins that are not physiological substrates of p38 MAP
kinase. Further experiments are therefore required to examine
the effect of p38 MAP kinase activation in the absence of p38
MAP kinase overexpression. These studies require the use of a
novel p38 MAP kinase activator. A candidate activator is
MKK6.
Molecular cloning of MKK6. The MAP kinase kinase
MKK6 was identified by screening a human skeletal muscle
cDNA library. Sequence analysis demonstrated the presence
of an open reading frame that encodes a protein kinase related
to the MAP kinase kinase group (Fig. 5A). In-frame termina-
tion codons present in the 59 and 39 noncoding regions indi-
cated that the MKK6 clones contained the complete coding
sequence. Two groups of clones with identical coding regions
but distinct 39 noncoding regions were identified. Comparison
FIG. 4. ATF2 and Elk-1 mediate transcriptional regulation by the MKK3-
p38 MAP kinase signal transduction pathway. (A) CHO cells were cotransfected
with the b-galactosidase expression vector pCH110, the reporter plasmid
pG5E1bLuc, and an expression vector for the GAL4 DNA binding domain
(residues 1 to 147) or the GAL4 DNA binding domain fused to the acidic
activation domain of VP16. The graph presents the effects of the expression of
S218E/S222D MEK1 or MKK3(Glu) and p38 MAP kinase. Cell extracts were
prepared at 48 h following transfection, and the activity of b-galactosidase and
luciferase was measured. The data are presented as the means 6 standard errors
of the means of the ratios of luciferase activity to b-galactosidase activity (n5 3).
(B to D) The transcriptional activities of GAL4-ATF2 and GAL4-ATF2(T69A/
T71A) (B), GAL4–Elk-1 and GAL4–Elk-1(S383A) (C), and GAL4–c-Jun and
GAL4–c-Jun(S63A/S73A) (D) were measured in cotransfection assays using the
reporter plasmid pG5E1bLuc. The data are the means 6 standard errors of the
means of the ratios of luciferase activity to b-galactosidase activity (n 5 3) and
are presented as the activity relative to that of control cells transfected with
GAL4-ATF2, GAL4–Elk-1, and GAL4–c-Jun, respectively. (E) Epitope-tagged
p38 MAP kinase was immunopurified from activated cells (40 J of UV-C per m2)
by immunoprecipitation with the Flag monoclonal antibody M2 and elution of
p38 MAP kinase by incubation with 100 mg of the Flag peptide MDYKDDDDK
per ml for 1 h at 48C. Kinase assays were performed with 1 mg of substrate
(GST-ATF2, GST-Jun, or GST–Elk-1) and 50 mM [g-32P]ATP. Control exper-
iments were performed by using GST as a substrate. The assays were terminated
after 20 min at 228C, and the reaction products were examined by SDS-PAGE
and autoradiography.
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of MKK6 with other humanMAP kinase kinases demonstrated
that MKK6 is most similar to the p38 MAP kinase activator
MKK3 (Fig. 5B).
The expression of MKK6 was examined by Northern blot
analysis of mRNA isolated from different human tissues. A
small transcript (approximately 1.7 kb) and a large transcript
(approximately 12 kb) were detected (data not shown). The
isolation of MKK6 cDNAs with alternative 39 untranslated
regions may account for the different mRNA transcripts de-
tected by hybridization analysis. The highest level of expression
was detected in skeletal muscle (data not shown).
MKK6 activates p38 MAP kinase in vitro. The substrate
specificity of MKK6 was examined by investigating the phos-
phorylation of MAP kinases (p38, JNK, and ERK) by MKK6
in an in vitro protein kinase assay. MKK6 phosphorylated p38
MAP kinase but not JNK1 or ERK2 (Fig. 6A). A low level of
MKK6 phosphorylation by activated p38 MAP kinase was also
detected (Fig. 6A). These data demonstrate that the substrate
specificity of MKK6 is similar to that of MKK3, a MAP kinase
kinase that selectively activates p38 MAP kinase (17). How-
ever, the specific activity of the MKK6 protein kinase was
approximately 300-fold greater than that of MKK3 (data not
shown).
The sites of p38 MAP kinase phosphorylation by MKK6
were examined by mutational analysis. Replacement of the p38
MAP kinase dual phosphorylation motif Thr-Gly-Tyr with the
phosphorylation-defective motif Ala-Gly-Phe (17, 44) blocked
the phosphorylation of p38 MAP kinase by MKK6 (Fig. 6B).
These data indicate that MKK6 phosphorylates p38 MAP ki-
nase on Thr-180 and Tyr-182, the sites of phosphorylation that
activate p38 MAP kinase (44).
The activation of p38 MAP kinase by MKK6 was examined
by measurement of p38 MAP kinase activity with the substrate
ATF2 (17, 44). This analysis demonstrated that MKK6 caused
p38 MAP kinase activation (Fig. 6C). In contrast, MKK6 did
not activate the phosphorylation-defective (Ala-Gly-Phe) p38
MAP kinase (Fig. 6C). Together, these data demonstrate that
MKK6 functions as a potent and selective activator of p38
MAP kinase in vitro.
MKK6 activates p38 MAP kinase in vivo. MKK6 protein
kinase activity was measured in an immune complex assay
using p38 MAP kinase as a substrate (17). Exposure of cells to
UV radiation caused increased MKK6 protein kinase activity
(Fig. 7A). Inclusion of the p38 MAP kinase substrate ATF2 in
the kinase assays demonstrated that the UV-activated MKK6
caused increased p38 MAP kinase activity (Fig. 6A). This anal-
ysis suggests that MKK6 may activate p38 MAP kinase in vivo.
MAP kinase kinases are activated by dual phosphorylation
within subdomain VIII (3, 9, 12, 29, 38, 52, 64). These phos-
phorylation sites are conserved in MKK6 (Ser-207 and Thr-
211). The mechanism of MKK6 activation may therefore be
mediated by increased negative charge on Ser-207 and Thr-
211. To test this hypothesis, we examined the effect of intro-
ducing a constitutive negative charge by replacing Ser-207 and
FIG. 5. Primary structure of human MKK protein kinases. (A) The primary
sequence of MKK6 was deduced from the sequences of cDNA clones isolated
from a human skeletal muscle library. In-frame stop codons are located in the 59
and 39 noncoding regions of the MKK6 cDNAs. The sequence of MKK6 was
compared with those of the human MAP kinase kinases MEK1 (51, 63), MEK2
(63), MKK3 (17), MKK4 (17, 36), and MKK5 (65) with the PILE-UP program
(version 7.2; Wisconsin Genetics Computer Group). The protein sequences are
presented in single-letter code. The MKK5 sequence is truncated at the NH2
terminus (,). Gaps introduced into the sequences to optimize the alignment are
illustrated with dashes. Identical residues are indicated with periods. The sites of
activating phosphorylation of MEK (3, 64) are indicated with asterisks. The
sequences of two MKK6 cDNA clones (1,699 and 2,942 bp) with identical coding
regions and alternative 39 untranslated regions have been deposited in GenBank
under accession numbers U39656 and U39657. (B) The relationships between
members of the humanMAP kinase kinase group are presented as a dendrogram
created by the unweighted pair-group method using arithmetic averages (PILE-
UP program). The human MAP kinase kinases MEK1, MEK2, MKK3, MKK4,
MKK5, and MKK6 are presented.
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Thr-211 with Glu. We coexpressed MKK6(Glu) with p38 MAP
kinase in cultured cells. The p38 MAP kinase activity was
measured in an immune complex kinase assay using the tran-
scription factor ATF2 as a substrate. MKK6(Glu) caused ac-
tivation of wild-type (Thr-Gly-Tyr) p38 MAP kinase but not
activation of the phosphorylation-defective (Ala-Gly-Phe) mu-
tant (Fig. 7B). In contrast, kinase-negative MKK6 did not
activate p38 MAP kinase (Fig. 7B). Together, these data dem-
onstrate that MKK6(Glu) is an activator of p38 MAP kinase in
vivo.
The activation of transfected p38 MAP kinase by MKK6(Glu)
(Fig. 7B) suggests that the expression of MKK6(Glu) may
activate the endogenous p38 MAP kinase in cultured cells. To
test this hypothesis, we compared the effects of MKK6(Glu) on
endogenous and transfected p38 MAP kinase. MKK6(Glu)
was found to efficiently activate both endogenous and overex-
pressed p38 MAP kinase (Fig. 7C). In contrast, a constitutively
activated mutant of the p38 MAP kinase activator MKK3
[MKK3(Glu)] that markedly stimulates overexpressed p38
MAP kinase (Fig. 2) caused only a small increase (twofold) in
the activity of endogenous p38 MAP kinase (Fig. 7C). These
data demonstrate that constitutively activated MKK6 (and not
MKK3) is an effective activator of endogenous p38 MAP ki-
nase in vivo. We therefore employed MKK6(Glu) in further
studies to examine the function of the p38 MAP kinase signal
transduction pathway.
MKK6 causes increased ATF2-dependent gene expression.
The transcription factor ATF2 is phosphorylated in vitro by
p38 MAP kinase on Thr-69 and Thr-71 (17, 44). Phosphoryla-
tion of ATF2 on these sites causes increased transcriptional
activation potential (23, 37, 58). To test whether ATF2 is
phosphorylated and activated by p38 MAP kinase in vivo, we
examined the effect of expression of MKK6(Glu) in cotrans-
fection assays (Fig. 8A). Increased ATF2-dependent gene ex-
pression was observed in cells transfected with MKK6(Glu). In
contrast, MKK3(Glu) did not increase ATF2-dependent gene
expression in the absence of overexpression of p38 MAP ki-
nase (Fig. 8A). These data are consistent with the potent ac-
tivation of p38 MAP kinase caused by MKK6(Glu) and with
the ineffective activation of endogenous p38 MAP kinase
caused by MKK3(Glu) (Fig. 7C).
The specificity of MKK6-stimulated ATF2-dependent gene
expression was examined in cotransfection assays (Fig. 8B).
MKK6(Glu) caused a marked increase in ATF2-dependent
reporter gene expression in experiments using wild-type (Thr-
69, Thr-71) ATF2. In contrast, the effect of MKK6(Glu) was
markedly reduced in experiments using phosphorylation-de-
fective (Ala-69, Ala-71) ATF2. Control experiments demon-
strated that wild-type MKK6 caused only a small increase in
reporter gene expression and that kinase-negative MKK6
(K82A) did not increase ATF2-dependent reporter gene ex-
pression. Together, these data confirm the hypothesis that
transcription factors are targets of the p38 MAP kinase signal
FIG. 6. MKK6 phosphorylates and activates p38 MAP kinase in vitro. (A)
Recombinant GST-MKK6 was incubated with [g-32P]ATP and buffer (—), GST-
JNK1 (JNK1), GST-p38 MAP kinase (p38), or GST-ERK2 (ERK2). The phos-
phorylation reaction was terminated by addition of Laemmli sample buffer, and
the phosphorylated proteins were detected after SDS-PAGE by autoradiogra-
phy. (B) GST-MKK6 was incubated with [g-32P]ATP and buffer (—), wild-type
GST-p38 MAP kinase (TGY), or mutated GST-p38 MAP kinase (AGF). In the
mutated p38 MAP kinase, Thr-180 and Tyr-182 were replaced with Ala and Phe,
respectively. The phosphorylated proteins were resolved by SDS-PAGE and
detected by autoradiography. (C) GST-MKK6 was incubated with [g-32P]ATP
and buffer, wild-type GST-p38 MAP kinase (TGY), or mutated GST-p38 MAP
kinase (AGF). The p38 MAP kinase substrate ATF2 was included in each
incubation (44). The phosphorylated proteins were resolved by SDS-PAGE and
detected by autoradiography.
FIG. 7. MKK6 phosphorylates and activates p38 MAP kinase in vivo. (A)
Cells expressing epitope-tagged MKK6 were exposed in the absence and pres-
ence of 40 J of UV-C per m2. MKK6 was isolated by immunoprecipitation and
used for protein kinase assays with p38 MAP kinase as a substrate. The tran-
scription factor ATF2 was included in the incubations as a substrate for p38
MAP kinase (17, 44). The phosphorylation reaction was initiated by the addition
of [g-32P]ATP and was terminated by the addition of Laemmli sample buffer.
The phosphorylated proteins were visualized after SDS-PAGE by autoradiogra-
phy. (B) Constitutively activated MKK6(Glu) and kinase-negative MKK6(K82A)
were expressed together with epitope-tagged wild-type p38 MAP kinase (TGY)
or mutated p38 MAP kinase (AGF). The mutated p38 MAP kinase is not a
substrate for MKK6, because it lacks the sites of activating phosphorylation on
Thr and Tyr (17). The p38 MAP kinase activity was measured in an immune
complex kinase assay using ATF2 as a substrate (17, 44). (C) MKK3(Glu),
MKK6(Glu), and p38 MAP kinase were expressed in cells that were activated by
exposure to 40 J of UV light per m2. p38 MAP kinase activity was measured in
an immune complex kinase assay with the substrate ATF2. Transfected and
endogenous p38 MAP kinase was assayed in an immune complex kinase assay
with a polyclonal p38 antibody (44).
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transduction pathway (44) and establish the utility of
MKK6(Glu) as a reagent that can be employed to dissect the
function of the p38 MAP kinase signal transduction pathway in
vivo.
DISCUSSION
Selective activation of the p38 MAP kinase signal transduc-
tion pathway. The p38 MAP kinase signal transduction path-
way is activated by proinflammatory cytokines and environ-
mental stress. These stimuli also activate other signal
transduction pathways. The identification of cellular responses
that are causally related to p38 MAP kinase activation is there-
fore difficult. Methods that allow the selective activation of the
p38 MAP kinase pathway are required. Here we report the use
of MKK3 and MKK6 as specific activators of p38 MAP kinase.
MKK3 is activated by phosphorylation on Ser-189 and Thr-193
(17). Similarly, MKK6 is activated by dual phosphorylation on
Ser-207 and Thr-211 (Fig. 5). Constitutively activated MKK3
and MKK6 mutants were constructed by replacing these phos-
phorylation sites with Glu residues. The constitutive activation
probably results from the presence of negative charges (Glu) at
the sites of activating phosphorylation. A similar approach has
been employed to create constitutively activated MEK1 to
increase ERK protein kinase activity in vivo (9, 12, 29, 38, 52).
The constitutively activated MAP kinase kinases MKK3
(Glu) and MKK6(Glu) may be generally applicable to studies
of the p38 MAP kinase signal transduction pathway in vivo. A
possible limitation of this approach is that p38 MAP kinase
activation may lead to increased cytokine expression (35) and
autocrine activation of additional signaling pathways in some
cells. However, for CHO cells and COS cells, the expression of
MKK3(Glu) or MKK6(Glu) was found to markedly activate
the p38 MAP kinase signal transduction pathway (Fig. 2 and
7).
Regulation of gene expression by p38 MAP kinase. To ex-
amine the role of the p38 MAP kinase signaling pathway, we
investigated the effect of MKK3(Glu) and MKK6(Glu) on
luciferase expression by using reporter plasmids containing
viral, proto-oncogene, and cytokine promoters. These studies
demonstrated that the p38 MAP kinase signaling pathway in-
creases gene expression. This increase in reporter gene expres-
sion caused by p38 MAP kinase activators may be accounted
for by a general effect of p38 MAP kinase on transcription or
by posttranscriptional actions of p38 MAP kinase (e.g., mRNA
processing, mRNA export, mRNA stability, and translation).
However, reporter gene expression from some promoters (e.g.,
the simian virus 40 promoter) was not significantly increased,
while marked increases in reporter gene expression were ob-
served in experiments using other promoters (e.g., the
HTLV-1 LTR promoter). This differential effect of p38 MAP
kinase activators in increasing luciferase expression in experi-
ments using different promoters indicates that the p38 MAP
kinase signal transduction pathway causes a selective increase
in gene expression.
To identify specific transcription factors that may mediate
the effects of the p38 MAP kinase signaling pathway, we ex-
amined the effect of p38 MAP kinase activators [MKK3(Glu)
and MKK6(Glu)] in cotransfection experiments using GAL4
fusion proteins. Small increases in reporter gene expression
were observed in experiments using GAL4/VP16 and GAL4/
Jun. These small increases may be mediated by posttranscrip-
tional effects of the p38 MAP kinase signaling pathway. In
contrast, p38 MAP kinase activators caused a larger increase in
reporter gene expression in experiments using GAL4/ATF2
and GAL4/Elk.
Although these data establish that transcription factors (e.g.,
ATF2 and Elk-1) are targets of the p38 MAP kinase signal
transduction pathway, they do not exclude the possibility that
p38 MAP kinase may also control gene expression by posttran-
scriptional regulation of specific gene transcripts. For example,
p38 MAP kinase may regulate tumor necrosis factor expression
(35) by regulating transcription, mRNA stability, and transla-
tion (26, 32, 33, 54). Further studies are required to identify the
molecular basis of these possible actions of p38 MAP kinase.
Transcription factor Elk-1 is regulated by the p38 MAP
kinase signal transduction pathway. Elk-1 is an ETS domain
transcription factor that binds together with serum response
factor to the SRE. Elk-1 contains a COOH terminal transcrip-
tional activation domain that is phosphorylated by the ERK
(21, 30, 39) and JNK (60) groups of MAP kinase. Expression of
activated MEK1 caused increased Elk-1-dependent reporter
gene expression (Fig. 4). Similar increases in Elk-1 transcrip-
tional activity were observed in cells transfected with
MKK3(Glu) (Fig. 4) and MKK6(Glu) (data not shown). Fur-
thermore, similar effects of ERK and p38 MAP kinase activa-
tors were observed in experiments using a reporter plasmid
containing the c-fos SRE (Fig. 3). Mutation of the Elk-1 phos-
phorylation site Ser-383 reduced the increases in luciferase
expression caused by both ERK and p38 MAP kinase activa-
tors (Fig. 4). Together, these data indicate that Elk-1 is a target
of all three groups of MAP kinase (p38, JNK, and ERK). Elk-1
therefore serves to integrate signals from multiple MAP kinase
signal transduction pathways in response to extracellular stim-
uli (Fig. 9). However, the effect of SRE activation is likely to
FIG. 8. Increased gene expression mediated by the MKK6-p38 MAP kinase
signal transduction pathway. (A) ATF2-dependent gene expression was exam-
ined in cotransfection assays using a luciferase reporter gene. Transfection effi-
ciency was monitored by measurement of b-galactosidase expression. The rela-
tive luciferase activities (means 6 standard deviations; n 5 3) detected following
transfection of the empty expression vector, MKK3(Glu), MKK6(Glu), and p38
MAP (p38 MAP K) kinase are presented. (B) Cells were transfected with
an empty expression vector (Control), MKK6 (WT), MKK6(Glu), and
MKK6(K82A). ATF2-dependent reporter gene expression was measured by
using wild-type ATF2 (Thr-69/71) and mutated, phosphorylation-defective ATF2
(Ala-69/71). The data are presented as relative luciferase activities (means 6
standard deviations; n 5 3).
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differ for each MAP kinase pathway because the SRE func-
tions with other promoter elements (which may be differen-
tially regulated by p38, JNK, and ERK) to control gene ex-
pression (46, 56).
Transcription factor ATF2 is regulated by the p38 MAP
kinase signal transduction pathway. The ATF2 transcription
factor is phosphorylated by p38 MAP kinase on Thr-69 and
Thr-71 (44). Phosphorylation of ATF2 on these sites causes
increased transcriptional activity in vivo (23, 37, 58). The phos-
phorylation of ATF2 by p38 MAP kinase may therefore ac-
count for the increases in ATF2-dependent reporter gene ex-
pression caused by the p38 MAP kinase activators MKK3(Glu)
and MKK6(Glu) (Fig. 4). The activation of the HTLV-1 LTR
(which binds ATF2 [59]) is consistent with this hypothesis (Fig.
3). Furthermore, the activation of ATF2 may account, in part,
for the increases in reporter gene expression caused by p38
MAP kinase activators in experiments using a fragment (bp
273 to 1170) of the c-jun promoter (Fig. 3) that binds ATF2
as a heterodimer with c-Jun (57, 58).
Control experiments demonstrated that the expression of
activated MEK1 (which stimulates the ERK group of MAP
kinases) did not increase ATF2-dependent reporter gene ex-
pression (Fig. 4). ATF2 is therefore not a target of the ERK
signal transduction pathway (Fig. 9). However, ATF2 is acti-
vated by the JNK signal transduction pathway (23, 37, 58).
Thus, both the p38 and JNK signaling pathways contribute to
the regulation of ATF2 transcriptional activity in cells exposed
to proinflammatory cytokines and environmental stress. It is
likely that the consequence of ATF2 activation by each of these
pathways is different. For example, the p38 MAP kinase acti-
vates ATF2 (Fig. 4), while JNK phosphorylates and activates
both ATF2 (23, 37) and c-Jun (1, 16, 31, 55). The ATF2–c-Jun
heterodimer (25) is therefore predicted to be differentially
regulated by the p38 and JNK signal transduction pathways.
Signaling of p38 MAP kinase in the nucleus. Activation of
p38 MAP kinase causes a selective increase in gene expression
(Fig. 4). The p38 MAP kinase pathway may increase gene
expression by a general effect on transcription, by the activa-
tion of specific transcription factors, or by posttranscriptional
regulation (mRNA processing, nuclear export, mRNA stabil-
ity, translation, and protein stability). Autocrine activation of
cells in response to p38 MAP kinase-stimulated cytokine ex-
pression (35) may contribute to these regulatory processes.
The results of this study indicate that part of the genetic re-
sponse to p38 MAP kinase activation is mediated by the direct
activation of transcription factors. Immunofluorescence micro-
scopic analysis demonstrates that p38 MAP kinase is present in
the nucleus and the cytoplasm (44). The nuclear targets of p38
MAP kinase include the transcription factors ATF2 and Elk-1
(Fig. 9).
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